Dong-A Pharm Presents Poster on Two EPS Patent Probiotic Strains at International Conference

Dong-A Pharmaceutical announced on the 27th that it presented the research results of two self-developed EPS patented probiotics (EPS DA-BACS, EPS DA-LAIM) at the 2023 IPC International Conference held in Bratislava, Slovakia, from the 20th to the 22nd.

At the '2023 IPC International Conference' held in Slovakia from the 20th to the 22nd, conference participants are viewing the poster session on 'Research Results of Two Dong-A Pharm EPS Patent Probiotics.'
[Photo by Dong-A Pharm]

IPC (International Scientific Conference on Probiotics, Prebiotics, Gut Microbiota and Health) is the world's largest academic conference in the fields of probiotics, prebiotics, gut health, and gut microbiota. Professors and professionals specializing in probiotics from over 80 countries worldwide participate to share the latest industry trends and related expertise.

EPS patented probiotics derived from the healthy intestines of Koreans are probiotics that harmoniously coexist with the gut microbiome through their ability to colonize and adapt to the intestines, including acid resistance, bile resistance, and pancreatic juice resistance. The EPS naturally produced by the strains is known to positively affect health by enhancing the strains' intestinal adhesion ability and activating the immune system.

At this conference, Dong-A Pharmaceutical presented a poster titled "Research Results on the Gastrointestinal Stability, Antioxidant, Immune, and Prebiotic Effects of Healthy Human-Derived Probiotics and Their Derived Metabolite EPS."

In vitro experimental results showed that 'EPS DA-LAIM' had superior antioxidant capacity compared to vitamin C and exhibited better anti-inflammatory effects and gastrointestinal stability (acid resistance, bile resistance, pancreatic juice resistance) than the same control strains. The prebiotic effect of EPS isolated from the strain was also confirmed to be superior to inulin. These research results were published in an SCI journal in November 2022.

The 'EPS DA-BACS' strain showed increased acid resistance among gastrointestinal stabilities due to the influence of EPS. It was also confirmed to have excellent bile resistance, pancreatic juice resistance, and intestinal adhesion ability. Additionally, it demonstrated inhibitory effects on harmful microorganisms and anti-inflammatory effects comparable to the anti-inflammatory drug dexamethasone. The EPS isolated from this strain showed excellent prebiotic effects by promoting the growth of beneficial bacteria and suppressing harmful bacteria. These research results were published in an SCI journal in December 2022.

This presentation is the result of years of research by Dong-A Pharmaceutical and Professor Youngseo Park’s team at Gachon University. Dong-A Pharmaceutical and Professor Youngseo Park’s team at Gachon University have continuously collaborated on joint research for EPS strain development, SCI paper publication, and composition patent registration.

A representative from Dong-A Pharmaceutical said, "We are pleased to have our technological capabilities in probiotic strains recognized by presenting the excellence of Dong-A Pharmaceutical’s two EPS patented probiotics at the IPC International Conference. We will continue research on EPS probiotics and plan to apply them to all Dong-A Pharmaceutical probiotic products in the future and expand into the business-to-business (B2B) sector."

This content was produced with the assistance of AI translation services.